Shenzhen Hepalink Pays $206 Million for Cytovance, a US CMO

Shenzhen Hepalink Pharma will acquire Cytovance® Biologics, a US biologics contract development manufacturing company, for $205.7 million plus unspecified contingency payments. Hepalink plans to retain Cytovance's management, its 178 employees and its Oklahoma City facilities. With its capital, Hepalink expects to accelerate Cytovance's expansion plans. This includes adding 5,000L and 10,000L mammalian reactors and 1,000L and 5,000L microbial fermentors. More details.... Stock Symbol: (SHZ: 002399) Share this with colleagues: // //